Lidocaine Hydrochloride And Epinephrine
Injection
Current Active — Day 5195
High impact — Only one manufacturer supplies this drug; any disruption leaves no immediate alternative source.
FDA shortage record
- Substance
- Lidocaine Hydrochloride And Epinephrine
- Manufacturers / suppliers
-
- Hospira, Inc.
- Hospira, Inc., a Pfizer Company
- Dosage form
- Injection
- Presentation
- Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03)
- Route(s)
- INFILTRATION, PERINEURAL
- Therapeutic category
- Anesthesia, Pediatric
- Package NDC
0409-3178-03- Initially posted
- 02/22/2012
- Days on shortage list
- 5195
- Current FDA status
- Current
- Shortage entries (current dataset)
- 1 record for Lidocaine Hydrochloride And Epinephrine
Reason and context
Reason reported: Other
Limited Supply Available. Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 844-646-4398.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- FDA Structured Product Label (SPL set ID
2f94f711-14c4-48ec-c5a3-c5ec4b8e8729). - FDA UNII identifier:
YKH834O4BH. - See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.